CPET in CF Patients With One G551D Mutation Taking VX770
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Ivacaftor will restore CFTR function in treated CF patients with the G551D mutation.
Improvement in ventilation, salt balance and well-being will contribute to better exercise
capacity at all levels of lung function. While potential improvements may be variable across
the spectrum of lung function, even small gains at low levels of FEV1 may have significant
benefit for some subjects.